Publications by authors named "L Belvisi"

Article Synopsis
  • Developing high-affinity monovalent ligands for lectins is difficult due to weak binding interactions, prompting research into covalent ligands for BC2L-C lectin, which is linked to severe respiratory infections in immunocompromised patients.
  • Antiadhesion therapy is gaining traction as a strategy against infections, particularly targeting bacterial lectins like BC2L-C-Nt, which recognizes specific blood group oligosaccharides in host cells.
  • Using computational methods, researchers created effective reversible covalent ligands that enhanced their binding affinity significantly, demonstrating the crucial role of specific ligand components in achieving this improved efficacy.
View Article and Find Full Text PDF

DC-SIGN (CD209) and L-SIGN (CD209L) are two C-type lectin receptors (CLRs) that facilitate SARS-CoV-2 infections as viral co-receptors. SARS-CoV-2 manipulates both DC-SIGN and L-SIGN for enhanced infection, leading to interest in developing receptor antagonists. Despite their structural similarity (82% sequence identity), they function differently.

View Article and Find Full Text PDF

The installation of aldehydes into synthetic protein ligands is an efficient strategy to engage protein lysine residues in remarkably stable imine bonds and augment the compound affinity and selectivity for their biological targets. The high frequency of lysine residues in proteins and the reversibility of the covalent ligand-protein bond support the application of aldehyde-bearing ligands, holding promises for their future use as drugs. This review highlights the increasing exploitation of salicylaldehyde modules in various classes of protein binders, aimed at the reversible-covalent engagement of lysine residues.

View Article and Find Full Text PDF

Opportunistic infections from multidrug-resistant pathogens such as are a threatening risk for hospital-bound patients suffering from immunocompromised conditions or cystic fibrosis. BC2L-C lectin has been linked to bacterial adhesion and biofilm formation, thus hindering its activity is seen as a promising strategy to reduce the severity of the infection. We recently described the first bifunctional ligands of the trimeric N-terminal domain of BC2L-C (BC2L-C-Nt), capable of simultaneously engaging its fucose-specific sugar binding site and a vicinal region at the interface between two monomers.

View Article and Find Full Text PDF

The inhibition of carbohydrate-lectin interactions is being explored as an efficient approach to anti adhesion therapy and biofilm destabilization, two alternative antimicrobial strategies that are being explored against resistant pathogens. BC2L-C is a new type of lectin from that binds (mammalian) fucosides at the -terminal domain and (bacterial) mannosides at the -terminal domain. This double carbohydrate specificity allows the lectin to crosslink host cells and bacterial cells.

View Article and Find Full Text PDF